This bill would prohibit any federal law from granting immunity to manufacturers of COVID-19 vaccines or limiting their liability for losses tied to vaccine administration or use. It explicitly references existing federal protections found in sections 319F-3, 2111, and 2122 of the Public Health Service Act and would bar such immunities from being applied to vaccine-makers.
The measure also preserves individuals’ ability to seek compensation through the Countermeasures Injury Compensation Program (CICP) or the National Vaccine Injury Compensation Program (NVICP), and it clarifies that seeking compensation under those programs does not bar civil actions in a separate forum. Finally, the act defines “COVID–19 vaccine” for the purpose of liability and applies retroactively to administrations before or after enactment.
At a Glance
What It Does
No federal law may immunize COVID-19 vaccine manufacturers or cap their liability for losses related to vaccination. The act references PHSA sections 319F–3, 2111, and 2122 as sources of immunity that cannot be used to shield manufacturers.
Who It Affects
Vaccine manufacturers, federal and state civil courts, and healthcare providers involved in vaccine administration are directly affected by the shift in potential liability exposure.
Why It Matters
It signals a shift from government-backed liability protections toward potential civil actions, altering risk profiles for manufacturers and potentially expanding avenues for redress for injured individuals.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The LIABLE Act takes aim at federal shield provisions surrounding COVID-19 vaccines. It bans any federal rule or statute from granting manufacturers immunity from suit or from placing caps on liability for losses connected to vaccine administration or use.
The bill explicitly cites existing protections in the Public Health Service Act (PHSA) and says those protections cannot be used to shield vaccine makers. Importantly, the bill leaves intact two compensation pathways for vaccine injuries: the Countermeasures Injury Compensation Program (CICP) and the National Vaccine Injury Compensation Program (NVICP).
It states that pursuing compensation through these programs does not automatically foreclose a separate civil action in court. The definition of what counts as a “COVID–19 vaccine” is tied to FDA licensing or authorization, and the act applies retroactively to vaccine actions both before and after enactment.
In short, the LIABLE Act curtails federal immunity and invites civil litigation or alternative compensation avenues for vaccine-related injuries, while maintaining existing federal compensation programs.
The Five Things You Need to Know
The bill prohibits federal immunity or liability caps for COVID-19 vaccine manufacturers.
It preserves the option to pursue compensation through CICP or NVICP without barring civil actions.
It defines COVID-19 vaccine as FDA-licensed vaccines aimed at preventing or mitigating COVID-19 or its transmission.
The act applies retroactively to vaccine administrations before or after enactment.
It references PHSA sections 319F–3, 2111, and 2122 as bases that cannot immunize manufacturers.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This act may be cited as the Let Injured Americans Be Legally Empowered Act, or the LIABLE Act.
No federal immunity from or limitation on liability for manufacturers
Section 2(a) bars any federal law from immunizing or limiting liability for losses arising from a COVID-19 vaccine. It targets the cited PHSA provisions (319F–3, 2111, 2122), ensuring that vaccine makers cannot be shielded from civil liability by federal rule or statute.
Rule of construction: compensation programs preserved
Nothing in this Act prevents individuals from seeking compensation through the Countermeasures Injury Compensation Program (CICP) or the NVICP. The Act preserves these avenues even as civil actions remain available. This preserves a federal path to compensation while not restricting private litigation.
Relation to other programs
An individual shall not be precluded from bringing a civil action for claims described in subsection (a) solely because they have sought or received compensation through CICP or NVICP. The Act thus allows parallel tracks—private litigation and existing compensation programs—for vaccine-related injuries.
Definition of COVID–19 vaccine
The term means a vaccine licensed or otherwise authorized by the FDA to prevent, mitigate, or limit the harm from COVID-19 or the transmission of SARS-CoV–2 or a related virus.
Retroactive applicability
The Act applies regardless of whether the vaccine administration occurred before, on, or after the date of enactment, ensuring the liability framework is uniform across time.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Injured individuals pursuing civil actions for vaccine-related harm, who gain access to potential damages outside of existing compensation programs.
- Plaintiff-side personal injury and product-liability lawyers who represent clients in vaccine-related claims.
- Federal and state civil courts that adjudicate vaccine-injury lawsuits and related dockets.
- Public-interest and patient-safety advocacy groups focused on accountability for vaccine safety and post-market remedies.
Who Bears the Cost
- Vaccine manufacturers face higher exposure to civil liability and potential damages.
- Insurance underwriters and risk pools that cover manufacturers may adjust premiums or coverage terms.
- Courts and administrative systems could incur higher litigation and docket management costs due to increased vaccine-injury filings.
Key Issues
The Core Tension
The central tension is between enabling civil redress for vaccine injuries and preserving stable incentives for vaccine development and distribution, all while managing the interplay between civil actions and federally administered compensation programs.
The LIABLE Act introduces a fundamental shift by removing federal immunities and liability caps for vaccine manufacturers, but it does not remove the safety nets of existing compensation programs. This creates a policy tension: individuals harmed by a vaccine may pursue civil actions, yet those same individuals retain the pathways to compensation through CICP and NVICP, potentially leading to split or overlapping claims.
The retroactive scope amplifies concerns about predictability for manufacturers and could influence how compensation programs handle duplicate or cross-claims. Implementation will also hinge on how courts interpret the interplay between federal liability expectations and state-level tort standards.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.